Latest Search
Quote
| Back Zoom + Zoom - Top | ||||
|
<Research>Citi Remains Positive on TIGERMED (03347.HK) 2026 Growth
Recommend 4 Positive 2 Negative 3 |
||||
|
||||
|
Industry data shows strong performance in China's innovative drug primary market financing in September 2025, with financing amount increasing by 322% YoY to US$557 million, Citi Research issued a research report saying. The total financing scale, including the secondary market, also grew by 82% to RMB11.8 billion. Based on recent trends in the innovative drug market, the broker maintained a positive outlook on TIGERMED (03347.HK) for new order growth in 4Q25 and 2026, with target price/ rating kept at $73/ Buy. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
